Department of Chronic Diseases and Metabolism, Research Group for Clinical and Experimental Endocrinology, KU Leuven - University of Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, Research Group for Vascular Surgery, KU Leuven - University of Leuven, Leuven, Belgium.
J Hum Nutr Diet. 2024 Aug;37(4):885-891. doi: 10.1111/jhn.13330. Epub 2024 Jun 4.
Lymphoedema is a chronic and progressive disease characterised by excessive accumulation of lymph in the interstitial compartment, leading to tissue swelling and fibroadipose deposition. Lymphangiogenesis is partly regulated by ketone body oxidation, and a ketogenic diet (KD) has shown therapeutic efficacy in a preclinical mouse tail lymphoedema model. Therefore, we aimed to investigate the potential therapeutic effect of a KD in patients with secondary lymphoedema.
Nine patients with unilateral stage 2 lymphoedema secondary to lymphadenectomy were included in this quasi-experimental exploratory study consisting of a short run-in phase to gradually induce ketosis, followed by a classic KD (CKD) and modified Atkins diet (MAD) phase during which patients consumed a CKD and MAD, respectively. Lymphatic function and oedema volume, the primary outcomes, were assessed at baseline and at the end of both the CKD and MAD phase. Secondary outcomes included health-related and lymphedema-specific quality of life (QoL).
Seven out of nine patients completed the study protocol. Lymphatic function was improved upon consumption of both a CKD (dermal backflow score [mean ± SD]: 7.29 ± 2.98 vs. 10.86 ± 2.19 at baseline; p = 0.03) and MAD (6.71 ± 2.06; p = 0.02), whereas oedema volume did not decrease during the course of the study (excess limb volume [mean ± SD]: 20.13 ± 10.25% at end of CKD and 24.07 ± 17.77% at end of MAD vs. 20.79 ± 12.96% at baseline; p > 0.99 and p > 0.30, respectively). No changes were observed in health-related, nor lymphoedema-specific QoL at the end of CKD and MAD.
The consumption of a KD improved lymphatic function and was associated with a clinically meaningful reduction in oedema volume in some patients (3/7 at end of CKD, 2/7 at end of MAD) with unilateral stage 2 secondary lymphoedema. These results highlight the potential of a KD to improve lymphatic function in patients with lymphoedema. However, further studies are required to substantiate our findings.
淋巴水肿是一种以间质间隙中淋巴液过度积聚为特征的慢性进行性疾病,导致组织肿胀和纤维脂肪沉积。酮体氧化部分调节淋巴管生成,生酮饮食(KD)在临床前小鼠尾淋巴水肿模型中显示出治疗效果。因此,我们旨在研究 KD 在继发性淋巴水肿患者中的潜在治疗效果。
本准实验性探索性研究纳入 9 例因淋巴结切除术导致单侧 2 期淋巴水肿的患者,该研究包括一个短期诱导酮症的运行阶段,随后是经典 KD(CKD)和改良 Atkins 饮食(MAD)阶段,在此期间患者分别摄入 CKD 和 MAD。主要结局是淋巴功能和水肿体积,在基线和 CKD 和 MAD 阶段结束时进行评估。次要结局包括健康相关和淋巴水肿特异性生活质量(QoL)。
9 例患者中有 7 例完成了研究方案。CKD(皮肤回流评分:[均值±标准差]:7.29±2.98 与 10.86±2.19,基线;p=0.03)和 MAD(6.71±2.06;p=0.02)摄入后淋巴功能均得到改善,而研究过程中水肿体积并未减少(过量肢体体积:CKD 结束时为 20.13±10.25%,MAD 结束时为 24.07±17.77%,基线时为 20.79±12.96%;p>0.99 和 p>0.30,分别)。CKD 和 MAD 结束时,健康相关和淋巴水肿特异性 QoL 均未发生变化。
KD 的摄入改善了淋巴功能,并与一些患者(CKD 结束时 3/7,MAD 结束时 2/7)单侧 2 期继发性淋巴水肿的水肿体积具有临床意义的减少相关。这些结果突出了 KD 改善淋巴水肿患者淋巴功能的潜力。然而,需要进一步的研究来证实我们的发现。